吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究

BACKGROUND AND OBJECTIVE: The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China. METHODS: We retrospectively reviewed 53 NSCLC patients treated with this agent at four hospital in China from Jan 01, 2004 to Jun 30, 2010. Survival analysis was evaluated by Kaplan-Meier method. RESULTS: A total of 53 patients were analyzed in this study (28 patients in second-line and 25 in third- or further-line treatment). The objective response rate (ORR) was 9.4%. The disease control rate (DCR) was 56.6%. The progression-free survival (PFS) and median overall survival (OS) was 3.0 and 17.6 months, respectively. Univariate analysis, revealed performance status (PS) score was an independent prognostic factor for overall survival. CONCLUSION: The GN agent is effective for the second-line or further- line treatment in advanced non-small cell lung cancer. The toxicity is well tolerated.